Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 financial results on Wednesday, November 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on November 5, 2025 at 8:00 am ET / 6 ...

Core Points - Nvidia-related stocks experienced a decline on Wednesday, with CoreWeave (CRWV.US) dropping over 5.4%, Arm Holdings (ARM.US) down more than 2%, Applied Digital (APLD.US) falling over 3%, and Recursion Pharmaceuticals (RXRX.US) and Nebius (NBIS.US) both decreasing by more than 5% [1] - Nvidia (NVDA.US) itself saw a slight decrease of 0.5% [1]

Core Viewpoint - Nvidia's holding concept stocks experienced a decline, with several key stocks dropping significantly [1] Group 1: Stock Performance - CoreWeave (CRWV.US) fell over 5.4% [1] - Arm Holdings (ARM.US) decreased by more than 2% [1] - Applied Digital (APLD.US) dropped over 3% [1] - Recursion Pharmaceuticals (RXRX.US) and Nebius (NBIS.US) both declined by more than 5% [1] - Nvidia (NVDA.US) itself saw a slight decrease of 0.5% [1]

Group 1 - Nvidia-related stocks experienced a decline, with CoreWeave (CRWV.US) dropping over 5.4%, Arm Holdings (ARM.US) down more than 2%, and Applied Digital (APLD.US) falling over 3% [1] - Recursion Pharmaceuticals (RXRX.US) and Nebius (NBIS.US) also saw declines exceeding 5% [1] - Nvidia (NVDA.US) itself decreased by 0.5% [1]

Group 1 - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is currently viewed as a speculative stock, with recent discussions highlighting its volatility and meme stock status [1][2] - The company utilizes automation, data science, and AI to enhance drug discovery, focusing on treatments for genetic, infectious, and cancer-related diseases [2] - Despite its potential, the stock has underperformed, with a notable decline since its previous higher valuations, leading to skepticism about its investment viability [2] Group 2 - There is a call for proof of concept before considering investment in Recursion Pharmaceuticals, as past performance has been disappointing [2] - Comparatively, other AI stocks are suggested to have better upside potential and lower downside risk, indicating a competitive landscape in the biotech and AI sectors [2]

Core Insights - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a significant stock price increase of 13.99% on Monday, closing at $6.68, as investors engaged in bargain-hunting following a two-day decline and repositioned their portfolios ahead of an upcoming earnings release [1][4]. Financial Performance - Recursion Pharmaceuticals is set to announce its third quarter financial results in the first week of November 2025 [2]. - The company reported a net loss of $171.9 million in the second quarter of the year, which is a 76% increase compared to a net loss of $97.5 million in the same period last year [2]. - Revenue for the company increased by 33% year-on-year, reaching $19.2 million, up from $14.4 million, primarily driven by collaboration agreements [3]. Company Overview - Recursion Pharmaceuticals is a clinical-stage biotechnology company that utilizes advanced machine-learning algorithms to analyze vast datasets, identifying numerous relationships across biology and chemistry [4]. - The company is notable for being one of the few that has received direct investment from technology giant Nvidia Corp. [4].

Key Points Recursion Pharmaceuticals' recent momentum is hard to explain. The company could soar even more if it makes strong clinical progress. Despite its innovative approach, the biotech looks risky. 10 stocks we like better than Recursion Pharmaceuticals › Many leading companies focused on artificial intelligence (AI) have seen their shares soar as they profit from the tailwind this market is currently experiencing. Perhaps a good way to cash in on this is to invest in smaller, under-the-rada ...

Company Performance - Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.36, showing a -6.33% change from the previous day's closing price, which lagged behind the S&P 500's daily loss of 0.63% [1] - Over the past month, shares of Recursion Pharmaceuticals have appreciated by 44.16%, outperforming the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92% [1] Upcoming Earnings - Analysts expect Recursion Pharmaceuticals to post earnings of -$0.35 per share in the upcoming earnings release, marking a year-over-year decline of 2.94% [2] - The current consensus estimate forecasts revenue to be $17.45 million, indicating a 33.11% decline compared to the same quarter of the previous year [2] Fiscal Year Projections - For the entire fiscal year, Zacks Consensus Estimates project earnings of -$1.5 per share and revenue of $72.38 million, representing changes of +11.24% and +23.02%, respectively, from the prior year [3] - Recent changes to analyst estimates for Recursion Pharmaceuticals reflect shifting dynamics in short-term business patterns, with positive estimate revisions indicating optimism about the business outlook [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a track record of exceeding expectations, with stocks rated 1 delivering an average annual return of +25% since 1988 [5] - Currently, Recursion Pharmaceuticals holds a Zacks Rank of 4 (Sell), with a 1.92% fall in the Zacks Consensus EPS estimate over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 84, placing it in the top 35% of all 250+ industries [6]

Core Insights - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has seen a significant stock price increase of 15.28%, closing at $6.79, following a major AI conference in Dubai [1][4] - The company's co-founder and CEO, Chris Gibson, highlighted the role of AI in shaping the future of Recursion, focusing on data generation, experiment automation, and AI-driven discoveries [2] - Chief Research and Development Officer, Najat Khan, is scheduled to participate in a virtual summit on October 29, discussing the democratization of small molecule drug discovery alongside MIT developers [3] Company Performance - Recursion Pharmaceuticals has extended its winning streak to three consecutive days, indicating strong investor interest and confidence in the company's direction [1][4] - The stock's performance is attributed to the positive reception of its AI initiatives and advancements in drug discovery technology [1][4] Technological Advancements - The company is utilizing Boltz-2, a biomolecular co-folding model that combines structure and binding affinity prediction, achieving accuracy comparable to physics-based free energy perturbation calculations but at speeds up to 1000 times faster [4]

Core Insights - Recursion Pharmaceuticals is positioned as a "TechBio company," emphasizing its integration of technology, particularly artificial intelligence (AI), in drug discovery and development [2][3] - The company has experienced significant stock decline, with an approximately 80% drop since its IPO in 2021, and a year-to-date decrease of around 5% [1] - Recursion's AI platform, Recursion OS 2.0, enhances the drug discovery process by identifying effective molecules and streamlining clinical trials [2][5] Company Overview - Recursion Pharmaceuticals utilizes AI and machine learning to improve the clinical trial process, potentially accelerating patient enrollment by 50% and enhancing evidence quality [3] - The company has established partnerships with major pharmaceutical firms, including Sanofi, Roche, Bayer, and Merck, indicating strong industry interest [3] Business Model and Opportunities - Recursion aims to achieve better, faster, and cheaper drug development, leveraging its AI platform to identify promising molecules for disease treatment [5] - The cost to file an Investigational New Drug (IND) application is significantly lower for Recursion at $10 million, compared to the industry average of around $27 million [6] - The company's pipeline includes four clinical-stage programs, with three focused on experimental cancer therapies currently in phase 1/2 trials [7]